OTCMKTS:BAYRY Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis $8.14 -0.08 (-0.97%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BAYRY alerts:Sign Up Key Stats Today's Range$8.09▼$8.1550-Day Range$7.25▼$8.5652-Week Range$4.79▼$8.65Volume303,236 shsAverage Volume812,230 shsMarket Capitalization$31.99 billionP/E RatioN/ADividend Yield0.25%Price TargetN/AConsensus RatingBuy Company Overview Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany. Read More Receive BAYRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BAYRY Stock News HeadlinesBayer’s Darolutamide Safety Study in Korea: Key Insights for InvestorsAugust 22, 2025 | msn.comBayer AG’s Innovative Phase I Study: A New Frontier in Cancer TreatmentAugust 22, 2025 | msn.comTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.August 28 at 2:00 AM | Crypto 101 Media (Ad)Bayer AG’s Promising Phase 3 Study on Prostate Cancer TreatmentAugust 22, 2025 | tipranks.comBayer AG’s New Pediatric Study: A Closer Look at Rivaroxaban for VTEAugust 22, 2025 | tipranks.comBayer’s Observational Study on Darolutamide: A Potential Game-Changer for Prostate Cancer TreatmentAugust 22, 2025 | tipranks.comBayer's E.L.Y. Wins “AI-based AgTech Solution of the Year” In 2025 AgTech Breakthrough Awards ProgramAugust 21, 2025 | globenewswire.comBayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded to "Strong-Buy" at Wall Street ZenAugust 21, 2025 | americanbankingnews.comSee More Headlines BAYRY Stock Analysis - Frequently Asked Questions How have BAYRY shares performed this year? Bayer Aktiengesellschaft's stock was trading at $4.88 at the beginning of 2025. Since then, BAYRY stock has increased by 66.6% and is now trading at $8.13. How were Bayer Aktiengesellschaft's earnings last quarter? Bayer Aktiengesellschaft (OTCMKTS:BAYRY) posted its quarterly earnings results on Wednesday, August, 6th. The company reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.10. The business had revenue of $12.42 billion for the quarter, compared to analyst estimates of $10.79 billion. Bayer Aktiengesellschaft had a positive trailing twelve-month return on equity of 15.44% and a negative net margin of 7.61%. Does Bayer Aktiengesellschaft have any subsidiaries? Bayer Aktiengesellschaft subsidiaries include these companies: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and others. How do I buy shares of Bayer Aktiengesellschaft? Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Large Cap Pharma Sub-IndustryN/A Current SymbolOTCMKTS:BAYRY CIK1144145 Webwww.bayer.com Phone49214301Fax49-21-4306-6328Employees92,815Year Founded1863Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E Ratio6.20 P/E GrowthN/ANet Income-$2.76 billion Net Margins-7.61% Pretax Margin-4.39% Return on Equity15.44% Return on Assets4.49% Debt Debt-to-Equity Ratio1.04 Current Ratio1.13 Quick Ratio0.73 Sales & Book Value Annual Sales$50.44 billion Price / Sales0.63 Cash Flow$3.71 per share Price / Cash Flow2.19 Book Value$8.81 per share Price / Book0.92Miscellaneous Outstanding Shares3,929,700,000Free FloatN/AMarket Cap$31.91 billion OptionableNot Optionable Beta0.91 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:BAYRY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.